Immune checkpoint inhibitors and adoptive cell transfer (ACT) of autologous tumor-infiltrating
T cells have shown durable responses in patients with melanoma. To study ACT and …

Dual-specificity tyrosine phosphorylation-regulated kinases (DYRK1A, 1B, 2-4) and cdc2-like
kinases (CLK1-4) belong to the CMGC group of serine/threonine kinases. These protein …

These findings demonstrate that a novel humanized mouse model can help clinical translation
of CAR-T cells against uveal and cutaneous melanoma that do not respond to TIL therapy …

Dual-specificity, tyrosine phosphorylation-regulated kinases (DYRKs) and cdc2-like kinases
(CLKs) play a large variety of cellular functions and are involved in several diseases (…

Background Small interfering RNAs (siRNAs) are powerful tools to control gene expression.
However, due to their poor cellular permeability and stability, their therapeutic development …

Dual-specificity, tyrosine phosphorylation-regulated kinases (DYRKs) and cdc2-like kinases
(CLKs) recently attracted attention due to their central involvement in various pathologies. …

Karonudib (TH1579) is a novel compound that exerts anti-tumor activities and has recently
entered phase I clinical testing. The aim of this study was to conduct a pre-clinical trial in …

Cancer immunotherapy can result in durable tumor regressions in some patients. However,
patients who initially respond often experience tumor progression. Here, we report …

Traumatic brain injury (TBI) is a risk factor for a group of neurodegenerative diseases termed
tauopathies, which includes Alzheimer's disease and chronic traumatic encephalopathy (…

The protein kinase DYRK1A is involved in Alzheimer’s disease, Down syndrome, diabetes,
viral infections, and leukemia. Leucettines, a family of 2-aminoimidazolin-4-ones derived …